Abstract Library

#3932 Artisan: Prospective phase II trial of TheraSphere Selective Internal Radiation Therapy (SIRT) for liver metastases in neuroendocrine tumors (NETs)

Introduction: The liver is the commonest site of metastases and is an independent predictor of poor outcome. SIRT allows delivery of high dose radiation to liver metastases and has shown promise in the management of NETs. We determined the safety and efficacy of SIRT in those with inoperable liver metastases in a prospective study.

Conference:

Presenting Author: Ahmed Q

Authors: Ahmed Q, Doumanoglou N, Evans J, Martinez M, Ward C,

Keywords: radioembolization, carcinoid, neuroendocrine, metastases,

#3707 Neoadjuvant PRRT with Y-90-DOTATOC – Preliminary results from a monocentric prospective study

Introduction: Surgery is considered the only curative option in pNET but is feasible only in a minority of patients. A new possible therapeutical strategy in pNETs is preoperative Peptide Receptor Radionuclide Therapy (PRRT) in order to increase the efficacy of surgery.

Conference:

Presenting Author: Grana C

Authors: Grana C, Papi S, Bertani E, Cascio A, Rocca P,

Keywords: PRRT, Y-90-Dotatoc, Neoadjuvant PRRT, pancreatic NET,

#3705 First results from IEO 676 clinical study of PRRT in neuroendocrine tumors – Is there still a space for Y-90-DOTATOC?

Introduction: IEO 676 is a prospective phase II study of Peptide Receptor Radionuclide Therapy (PRRT) with Y-90-DOTATOC in progressive G1, G2, G3, neuroendocrine patients. PRRT has been in use since the late 1990s, with the introduction of 90Y-DOTATOC, which allowed objective responses in 10-30% of treated patients.

Conference:

Presenting Author: Grana C

Authors: Grana C, Papi S, Clerici I, Rocca P, Spada F,

Keywords: PRRT, Y-90-DOTATOC, NET,

#3304 Ga-68/Lu-177 octreotate theranostic paradigm in metastatic Merkel cell carcinoma

Introduction: Merkel cell carcinoma (MCC) is a rare, aggressive, cutaneous neuroendocrine tumor with poor survival and significant propensity for metastasising. MCC is normally characterised by an up-regulation of somatostatin receptors (SSTR) which introduces the possibility for a targeted treatment approach using peptide receptor radionuclide therapy (PRRT).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Lenzo N

Authors: Falzone N, Meyrick D, Lee B, Lenzo N,

Keywords: peptide receptor radionuclide therapy, Merkel cell carcinoma, Lu-177 octreotate, Ac-225 octreotate,

#3189 Real-world outcomes of patients with neuroendocrine liver metastases treated with trans-arterial radioembolization: Results from CIRT, a large European prospective multi-centre observational study

Introduction: Trans-arterial radioembolization (TARE) is a treatment option for patients with liver dominant metastases from neuroendocrine tumors (mNET). The CIRSE Registry for SIR-Spheres Therapy (CIRT) is a European prospective multi-centre observational study conducted by the Cardiovascular and Interventional Radiological Society of Europe (CIRSE).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Helmberger T

Authors: Helmberger T, Schaefer N, Pech M, Pfammatter T, Maleux G,

Keywords: liver metastases, observational study, yttrium-90, trans-arterial radioembolization, registry, therapeutic embolization, SIRT,